913 related articles for article (PubMed ID: 18347795)
21. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
22. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
24. Clinical studies with epothilones for the treatment of metastatic breast cancer.
Vahdat LT
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
[TBL] [Abstract][Full Text] [Related]
25. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
26. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Cigler T; Vahdat L
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
[TBL] [Abstract][Full Text] [Related]
27. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
29. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
30. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
31. Current perspectives of epothilones in breast cancer.
Cardoso F; de Azambuja E; Lago LD
Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
[TBL] [Abstract][Full Text] [Related]
32. Epothilones in breast cancer: current status and future directions.
Atzori F; Fornier M
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
[TBL] [Abstract][Full Text] [Related]
33. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
Bhushan S; Walko CM
Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
[TBL] [Abstract][Full Text] [Related]
34. Preclinical investigations with epothilones in breast cancer models.
Burris HA
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
[TBL] [Abstract][Full Text] [Related]
35. Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
Villegas C; González-Chavarría I; Burgos V; Iturra-Beiza H; Ulrich H; Paz C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047035
[TBL] [Abstract][Full Text] [Related]
36. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Fornier M
Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
[TBL] [Abstract][Full Text] [Related]
37. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.
Rivera E
Breast J; 2010; 16(3):252-63. PubMed ID: 20408828
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
[TBL] [Abstract][Full Text] [Related]
40. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues.
Fornier MN
Clin Breast Cancer; 2007 Oct; 7(10):757-63. PubMed ID: 18021476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]